Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' FAY JW' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 42 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Nash, RA; Antin, JH; Karanes, C; Fay, JW; Avalos, BR; Yeager, AM; Przepiorka, D; Davies, S; Petersen, FB; Bartels, P; Buell, D; Fitzsimmons, W; Anasetti, C; Storb, R; Ratanatharathorn, V
      Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors

      BLOOD
    2. Fleming, DR; Wolff, SN; Fay, JW; Brown, RA; Lynch, JP; Bolwell, BJ; Stevens, DA; Goodman, SA; Greer, JP; Stein, RS; Pineiro, LA; Collins, RH; Goldsmith, LJ; Herzig, GP; Herzig, RH
      Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the north American marrow transplant group

      LEUKEMIA & LYMPHOMA
    3. Przepiorka, D; Devine, SM; Fay, JW; Uberti, JP; Wingard, JR
      Practical considerations in the use of tacrolimus for allogeneic marrow transplantation

      BONE MARROW TRANSPLANTATION
    4. Rowlings, PA; Williams, SF; Antman, KH; Fields, KK; Fay, JW; Reed, E; Pelz, CJ; Klein, JP; Sobocinski, KA; Kennedy, MJ; Freytes, CO; McCarthy, PL; Herzig, RH; Stadtmauer, EA; Lazarus, HM; Pecora, AL; Bitran, JD; Wolff, SN; Gale, RP; Armitage, JO; Vaughan, WP; Spitzer, G; Horowitz, MM
      Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    5. COLLINS RH; PINEIRO LA; AGURA ED; FAY JW
      TREATMENT OF T-PROLYMPHOCYTIC LEUKEMIA WITH ALLOGENEIC BONE-MARROW TRANSPLANTATION

      Bone marrow transplantation
    6. RATANATHARATHORN V; NASH RA; PRZEPIORKA D; DEVINE SM; KLEIN JL; WEISDORF D; FAY JW; NADEMANEE A; ANTIN JH; CHRISTIANSEN NP; VANDERJAGT R; HERZIG RH; LITZOW MR; WOLFF SN; LONGO WL; PETERSEN FB; KARANES C; AVALOS B; STORB R; BUELL DN; MAHER RM; FITZSIMMONS WE; WINGARD JR
      PHASE-III STUDY COMPARING METHOTREXATE AND TACROLIMUS (PROGRAF, FK506) WITH METHOTREXATE AND CYCLOSPORINE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS AFTER HLA-IDENTICAL SIBLING BONE-MARROW TRANSPLANTATION

      Blood
    7. BERNSTEIN SH; NADEMANEE AP; VOSE JM; TRICOT G; FAY JW; NEGRIN RS; DIPERSIO J; RONDON G; CHAMPLIN R; BARNETT MJ; CORNETTA K; HERZIG GP; VAUGHAN W; GEILS G; KEATING J; MESSNER H; WOLFF SN; MILLER KB; LINKER C; CAIRO M; HELLMANN S; ASHBY M; STRYKER S; NASH RA
      A MULTICENTER STUDY OF PLATELET RECOVERY AND UTILIZATION IN PATIENTS AFTER MYELOABLATIVE THERAPY AND HEMATOPOIETIC STEM-CELL TRANSPLANTATION

      Blood
    8. ANTMAN KH; ROWLINGS PA; VAUGHAN WP; PELZ CJ; FAY JW; FIELDS KK; FREYTES CO; GALE RP; HILLNER BE; HOLLAND HK; KENNEDY MJ; KLEIN JP; LAZARUS HM; MCCARTHY PL; SAEZ R; SPITZER G; STADTMAUER EA; WILLIAMS SF; WOLFF S; SOBOCINSKI KA; ARMITAGE JO; HOROWITZ MM
      HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM-CELL SUPPORT FOR BREAST-CANCER IN NORTH-AMERICA

      Journal of clinical oncology
    9. WINGARD JR; NASH RA; RATANATHARATHORN V; FAY JW; KLEIN JL; PRZEPIORKA D; MAHER RM; DEVINE SM; BOSWELL G; BEKERSKY I; FITZSIMMONS W
      LACK OF INTERACTION BETWEEN TACROLIMUS (FK506) AND METHOTREXATE IN BONE-MARROW TRANSPLANT RECIPIENTS

      Bone marrow transplantation
    10. BLUM JL; JONES SE; FAY JW; SENZER N; MENNEL RG
      GUIDELINES FOR SYSTEMIC THERAPY OF EARLY-STAGE BREAST-CANCER

      Breast cancer research and treatment
    11. OSHAUGHNESSY PT; BARSOTTI MG; FAY JW; TIGHE SW
      EVALUATING PARTICLE COUNTERS

      Journal - American Water Works Association
    12. BROWN RA; WOLFF SN; FAY JW; PINEIRO L; COLLINS RH; LYNCH JP; STEVENS D; GREER J; HERZIG RH; HERZIG GP
      HIGH-DOSE ETOPOSIDE, CYCLOPHOSPHAMIDE AND TOTAL-BODY IRRADIATION WITHALLOGENEIC BONE-MARROW TRANSPLANTATION FOR RESISTANT ACUTE MYELOID-LEUKEMIA - A STUDY BY THE NORTH-AMERICAN MARROW TRANSPLANT GROUP

      Leukemia & lymphoma
    13. FAY JW; BERNSTEIN SH
      RECOMBINANT HUMAN INTERLEUKIN-3 AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR MALIGNANT-LYMPHOMA

      Seminars in oncology
    14. HERZIG RH; LYNCH J; CHRISTIANSEN NP; FAY JW; DAVIS MP; HERZIG GP
      DOSE-INTENSIVE CHEMOTHERAPY WITH ETOPOSIDE-CYCLOPHOSPHAMIDE FOR ADVANCED BREAST-CANCER

      Seminars in oncology
    15. NASH RA; PINEIRO LA; STORB R; DEEG HJ; FITZSIMMONS WE; FURLONG T; HANSEN JA; GOOLEY T; MAHER RM; MARTIN P; MCSWEENEY PA; SULLIVAN KM; ANASETTI C; FAY JW
      FK506 IN COMBINATION WITH METHOTREXATE FOR THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE AFTER MARROW TRANSPLANTATION FROM MATCHED UNRELATED DONORS

      Blood
    16. STONE MJ; SAUSVILLE EA; FAY JW; HEADLEE D; COLLINS RH; FIGG WD; STETLERSTEVENSON M; JAIN V; JAFFE ES; SOLOMON D; LUSH RM; SENDEROWICZ A; GHETIE V; SCHINDLER J; UHR JW; VITETTA ES
      A PHASE-I STUDY OF BOLUS VERSUS CONTINUOUS-INFUSION OF THE ANTI-CD19 IMMUNOTOXIN, IGG-HD37-DGA, IN PATIENTS WITH B-CELL LYMPHOMA

      Blood
    17. ARROWSMITH ER; GOODMAN SA; COLLINS RH; WOOD S; GREER JP; EDWARDS J; STEIN RS; BRANDT SA; PINEIRO LA; STEIN B; KALLIANPUR A; FAY JW; WOLFF SN
      MIS-MATCHED (MM) RELATED ALLOGENEIC (ALLO) BONE-MARROW TRANSPLANTATION (BMT) - ANALYSIS OF PROGNOSTIC FACTORS AND LONG-TERM SURVIVAL (LTS)

      Blood
    18. FAY JW; AGURA E; COLLINS R; PINEIRO L
      PREVENTION OF GRAFT-VERSUS-HOST (GVHD) AFTER UNRELATED MARROW TRANSPLANTATION THERAPY (UMT) USING TACROLIMUS (FK506) AND PREDNISONE

      Blood
    19. RATANATHARATHORN V; NASH RA; DEVINE SM; PRZEPIORKA D; KLEIN JL; WEISDORF DJ; FAY JW; NADEMANEE AP; ANTIN JH; KARANES C; AVALOS BR; CHRISTIANSEN NP; VANDERJAGT RH; HERZIG RH; LITZOW MR; WOLFF SN; LONGO WR; PETERSEN FB; BUELL DN; MAHER RM; FITZSIMMONS WE; WINGARD JR
      PHASE-III STUDY COMPARING TACROLIMUS (PROGRAF(R), FK506) WITH CYCLOSPORINE FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS AFTER HLA-IDENTICAL SIBLING BONE-MARROW TRANSPLANTATION (BMT)

      Blood
    20. WINGARD JR; NASH RA; PRZEPIORKA D; KLEIN JL; WEISDORF DJ; FAY JW; ZHU J; MAHER RM; FITZSIMMONS WE; RATANATHARATHORN V
      RELATIONSHIPS OF TACROLIMUS (PROGRAF(R), FK506) WHOLE-BLOOD CONCENTRATIONS AND EFFICACY AND SAFETY AFTER HLA-IDENTICAL SIBLING BONE-MARROW TRANSPLANTATION (BMT)

      Blood
    21. ROSENFELD CS; WEINTHAL JW; COLLINS RW; AGURA ED; LENARSKY C; PINEIRO L; NEMUNAITIS J; FAY JW
      DOES CD38 CONTENT OF ALLOGENEIC BLOOD-CELL - TRANSPLANTS PREDICT ACUTE GVHD

      Blood
    22. FAY JW; WINGARD JR; ANTIN JH; COLLINS RH; PINEIRO LA; BLAZAR BR; SARAL R; BIERER BE; PRZEPIORKA D; FITZSIMMONS WE; MAHER RM; WEISDORF DJ
      FK506 (TACROLIMUS) MONOTHERAPY FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE AFTER HISTOCOMPATIBLE SIBLING ALLOGENEIC BONE-MARROW TRANSPLANTATION

      Blood
    23. BAER MR; BERNSTEIN SH; BRUNETTO VL; HEINONEN K; MROZEK K; SWANN VL; MINDERMAN H; BLOCK AW; PIXLEY LA; CHRISTIANSEN NP; FAY JW; BARCOS M; RUSTUM Y; HERZIG GP; BLOOMFIELD CD
      BIOLOGICAL EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH UNTREATED ACUTE MYELOID-LEUKEMIA

      Blood
    24. ROSS AA; MILLER GW; MOSS TJ; KAHN DG; WARNER NE; SWEET DL; LOUIE KG; SCHNEIDERMANN E; PECORA AL; MEAGHER RC; HERZIG RH; COLLINS RH; FAY JW
      IMMUNOCYTOCHEMICAL DETECTION OF TUMOR-CELLS IN BONE-MARROW AND PERIPHERAL-BLOOD STEM-CELL COLLECTIONS FROM PATIENTS WITH OVARIAN-CANCER

      Bone marrow transplantation
    25. FAY JW; NASH RA; WINGARD JR; PRZEPIORKA D; COLLINS RH; ANASETTI C; DEVINE SM; PINEIRO LA; STORB RF; ARO RM; FITZSIMMONS WE
      FK 506-BASED IMMUNOSUPPRESSION FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE AFTER UNRELATED DONOR MARROW TRANSPLANTATION

      Transplantation proceedings
    26. COLLINS RH; PINEIRO LA; NEMUNAITIS JJ; JAIN VK; WAXMAN D; MILLER WV; FAY JW
      TRANSFUSION OF DONOR BUFFY COAT CELLS IN THE TREATMENT OF PERSISTENT OR RECURRENT MALIGNANCY AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION

      Transfusion
    27. FAY JW; FELSER JM; ABBOUD C; BORSON R; FREYTES C; HERZIG R; HURD D; JANAKIRAMAN N; JANSEN J; LAZARUS H; LYNCH JP; MANGAN KF; SAEZ R; STEVENS DA; WOLFF SN; YANOVICH S; STIFF P
      SEQUENTIAL ADMINISTRATION OF RECOMBINANT HUMAN INTERLEUKIN-3 (IL-3) AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) THERAPY FOR LYMPHOMA - RESULTS OF A PHASE-III MULTICENTER STUDY

      Blood
    28. NANTEL SH; BERNSTEIN SH; STEVENS DA; FAY JW; HERZIG RH; PHILLIPS GL; HERZIG GP; GARRISON L
      DOSE-ESCALATION STUDY OF PIXY321 POST AUTOLOGOUS BONE-MARROW TRANSPLANT (BMT) FOR HODGKINS-DISEASE (HD) OR NON-HODGKINS-LYMPHOMA (NHL)

      Blood
    29. WINGARD JR; NASH RA; RATANATHARATHORN V; FAY JW; KLEIN JL; PRZEPIORKA D; DEVINE SM; FITZSIMMONS WE
      LACK OF INTERACTION BETWEEN TACROLIMUS (FK506) AND METHOTREXATE (MTX)IN BONE-MARROW TRANSPLANT (BMT) RECIPIENTS

      Blood
    30. BERNSTEIN SH; FAY JW; CHRISTIANSEN N; PINERO L; HERZIG R; HERZIG G
      SEQUENTIAL INTERLEUKIN-3 (IL-3) AND GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) PRIMING OF HIGH-DOSE ETOPOSIDE (VP) AND CYCLOPHOSPHAMIDE (CY) - A PHASE I II TRIAL/

      Blood
    31. STONE RM; PIRO ID; SAVEN A; BERG DT; BRYAN WJ; FAY JW; HERZIG GP; HERZIG RH; SHIELDS AF; COLEMAN BS; LEE EJ
      A PHASE-I NOVEL ALKYLATING AGENT (AA), ADOZELESIN PATIENTS (PTS) WITHREFRACTORY HEMATOLOGIC MALIGNANCIES (HM)

      Blood
    32. BROWN RA; WOLFF SN; FAY JW; PINEIRO L; COLLINS RH; LYNCH JP; STEVENS D; GREER J; HERZIG RH; HERZIG GP
      HIGH-DOSE ETOPOSIDE, CYCLOPHOSPHAMIDE, AND TOTAL-BODY IRRADIATION WITH ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID-LEUKEMIA IN UNTREATED FIRST RELAPSE - A STUDY BY THE NORTH-AMERICANMARROW TRANSPLANT GROUP

      Blood
    33. NIKAEIN A; POOLE T; FISHBECK R; ORDONEZ G; DOMBRAUSKY L; STONE MJ; COLLINS RH; FAY JW
      CHARACTERIZATION OF SKIN-INFILTRATING CELLS DURING ACUTE GRAFT-VERSUS-HOST DISEASE FOLLOWING BONE-MARROW TRANSPLANTATION USING UNRELATED MARROW DONORS

      Human immunology
    34. NIKAEIN A; COLLINS RH; KLINTMALM G; POOLE T; FAY JW; STONE MJ
      IMMUNOLOGICAL MONITORING OF GRAFT-VERSUS-HOST DISEASE FOLLOWING ORTHOTOPIC LIVER-TRANSPLANTATION

      Transplantation
    35. COLLINS RH; FAY JW
      TREATMENT OF LEUKEMIA IN RELAPSE AFTER BONE-MARROW TRANSPLANTATION

      The New England journal of medicine
    36. FAY JW; LAZARUS H; HERZIG R; SAEZ R; STEVENS DA; COLLINS RH; PINEIRO LA; COOPER BW; DICESARE J; CAMPION M; FELSER JM; HERZIG G; BERNSTEIN SH
      SEQUENTIAL ADMINISTRATION OF RECOMBINANT HUMAN INTERLEUKIN-3 AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR MALIGNANT-LYMPHOMA - A PHASE I II MULTICENTER STUDY/

      Blood
    37. FAY JW; PINEIRO L; COLLINS RH; STEIN B; ARO RM; FITZSIMMONS WE
      FK506-BASED IMMUNOSUPPRESSION FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER UNRELATED MARROW DONOR (UMD) TRANSPLANTATION

      Blood
    38. MCCARTHY PL; WILLIAMS L; HARRISBACILE M; PRZEPIORKA D; CHAMPLIN RE; FAY JW; ANASETTI C; BECK C; JACOBS C
      PHASE-I II CLINICAL-STUDY OF SOLUBLE INTERLEUKIN-1 RECEPTOR (SIL-1R) IN STEROID-RESISTANT GRAFT-VERSUS-HOST DISEASE (GVHD)/

      Blood
    39. FAY JW; FELSER J; LAZARUS HM; HERZIG R; SAEZ R; STEVENS D; COLLINS RH; PINERO L; COOPER B; HERZIG GP; CAMPION M; DICESARE J; BERNSTEIN SH
      SEQUENTIAL ADMINISTRATION OF INTERLEUKIN-3 (RHIL-3) AND RHGM-CSF FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION - AN UPDATE OF THE PHASE-I II TRIAL/

      Blood
    40. FAY JW; COLLINS RH; PINEIRO LA; NEMUNAITIS JJ; ARO R; FITZSIMMONS W
      FK506 TO PREVENT GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER ALLOGENEIC MARROW TRANSPLANTATION (AMT) USING UNRELATED MARROW DONORS (UMD)-A PHASE-II STUDY

      Blood
    41. FAY JW; COLLINS R; PINEIRO L; DUTCHER J; GUCALP R; GRINBLATT D; LAZARUS HM; WILLIAMS S; COOPER BW; MANFREDA S; ISAACS R
      CONCOMITANT ADMINISTRATION OF INTERLEUKIN-6 (RHIL-6) AND LEUCOMAX(R) (RHGM-CSF) FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION-A PHASE-I TRAIL

      Blood
    42. WOLFF SN; FAY JW; HERZIG RH; GREER JP; DUMMER S; BROWN RA; COLLINS RH; STEVENS DA; HERZIG GP
      HIGH-DOSE WEEKLY INTRAVENOUS IMMUNOGLOBULIN TO PREVENT INFECTIONS IN PATIENTS UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION OR SEVERE MYELOSUPPRESSIVE THERAPY - A STUDY OF THE AMERICAN-BONE-MARROW-TRANSPLANT-GROUP

      Annals of internal medicine


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/08/20 alle ore 22:58:02